search
new
biomark
diagnosi
prognosi
therapeut
monitor
diseas
continu
earnest
despit
dwindl
success
find
novel
reliabl
marker
current
marker
clinic
use
provid
optim
sensit
specif
prostat
cancer
antigen
psa
one
mani
exampl
emerg
proteom
techniqu
system
approach
studi
diseas
pathophysiolog
rekindl
quest
new
biomark
particular
use
protein
microarray
surg
power
tool
larg
scale
test
biolog
sampl
approxim
half
report
protein
microarray
publish
last
two
year
especi
area
biomark
discoveri
review
discuss
applic
protein
microarray
technolog
offer
uniqu
opportun
find
novel
biomark
discoveri
novel
biomark
earli
detect
diseas
patient
stratif
monitor
therapi
diseas
progress
major
thrust
biomed
research
biomark
surrog
measur
enabl
predict
clinic
physiolog
state
ideal
easi
measur
inexpens
noninvas
highli
accur
make
intend
predict
clinic
practic
hand
biomark
use
today
exampl
elev
troponin
serum
suggest
myocardi
infarct
increas
cancer
antigen
level
like
ca
psa
use
detect
monitor
ovarian
prostat
cancer
respect
detect
autoantibodi
antinuclear
protein
may
reveal
patient
autoimmun
diseas
like
system
lupu
erythematosu
increas
shift
toward
person
care
individu
base
upon
specif
diseas
creat
greater
demand
biomark
diagnos
stratifi
patient
yet
exist
biomark
major
diseas
sensit
specif
mani
current
marker
ideal
despit
larg
demand
current
rate
discoveri
valid
molecular
diagnost
marker
declin
larg
scale
approach
genom
proteom
provid
tool
enabl
ask
question
global
system
level
empow
screen
method
discov
biomark
recent
advanc
proteom
technolog
includ
mass
spectrometri
protein
microarray
enabl
largescal
screen
protein
tissu
serum
patient
applic
biomark
discoveri
protein
microarray
allow
simultan
rapid
analysi
thousand
protein
highthroughput
ht
microarray
use
survey
antigen
antibodi
blood
sampl
biolog
fluid
inform
biomark
howev
signific
challeng
still
remain
develop
valid
appli
technolog
effect
identifi
biomark
clinic
use
articl
review
applic
variou
type
protein
microarray
technolog
biomark
discoveri
tool
discov
peptid
antigen
develop
antibodi
base
captur
array
antibodi
array
antibodi
print
onto
array
surfac
design
captur
measur
rel
abund
cognat
antigen
fig
offer
capabl
measur
level
multipl
analyt
biolog
sampl
like
serum
plasma
tissu
etc
simultan
abil
antibodi
captur
detect
analyt
high
affin
select
make
array
well
suit
detect
rare
analyt
complex
sampl
select
high
affin
reagent
antibodi
found
broad
applic
solut
assay
western
blot
elisa
immunohistochem
stain
etc
earli
use
antibodi
protein
microarray
demonstr
haab
et
al
author
test
pair
antibodyantigen
interactor
context
protein
array
despit
strong
evid
antibodi
bound
well
solut
assay
found
array
print
antibodi
could
detect
cognat
antigen
pool
antigen
antibodi
could
quantit
detect
differ
concentr
antigen
studi
illustr
although
mani
antibodi
work
well
solutionbas
detect
reagent
fraction
may
work
print
array
may
due
loss
antibodi
activ
denatur
print
array
storag
altern
might
reflect
mani
antibodi
character
denatur
protein
thu
recogn
linear
epitop
antigen
ad
array
solut
linear
epitop
may
buri
fold
protein
mani
antibodi
work
well
western
elisa
fail
work
immunoprecipit
exampl
interestingli
experi
invert
antigen
array
probe
pool
antibodi
much
larger
number
antibodyantigen
pair
detect
behav
quantit
final
author
point
certain
antigen
may
labil
sensit
direct
label
wherea
antibodi
like
label
uniformli
earli
work
haab
et
al
demonstr
use
antibodi
array
measur
low
concentr
analyt
highlight
import
qualifi
antibodi
use
microarray
test
whether
antibodi
array
use
detect
antigen
complex
protein
lysat
sreekumar
et
al
profil
cancer
antigen
author
use
cancer
cell
lysat
cell
treat
without
direct
exposur
radiat
probe
antibodi
array
compris
antibodi
protein
treatment
differenti
label
dual
color
fluorophor
mix
togeth
cross
label
lysat
done
avoid
experiment
bia
due
dye
effect
sever
antigen
regul
radiationinduc
cell
name
icad
well
trail
among
other
major
protein
unchang
one
protein
cea
regul
studi
demonstr
first
use
antibodi
array
monitor
chang
level
antigen
fluoresc
label
complex
protein
sampl
measur
candid
antigen
reli
specif
singl
target
antibodi
author
confirm
specif
find
use
immunoblot
assay
sever
technic
issu
aris
use
direct
protein
label
includ
differenti
label
effici
need
reli
sole
specif
print
captur
antibodi
specif
reduc
risk
cross
reactiv
huang
et
al
use
sandwich
assay
measur
level
cytokin
condit
media
patient
sera
use
antibodi
pair
recogn
differ
epitop
singl
antigen
one
antibodi
immobil
array
captur
antigen
coupl
hrp
chemiluminesc
detect
fig
sensit
dynam
rang
detect
cytokin
approach
compar
better
obtain
commerci
elisa
improv
specif
sandwich
assay
minim
concern
aberr
signal
cross
react
signal
singl
antibodi
howev
exist
limit
set
antibodi
satisfi
requir
sandwich
assay
first
need
two
high
qualiti
antibodi
recogn
differ
epitop
antigen
second
absenc
cross
reactiv
antibodi
antigen
test
assay
case
cytokin
numer
wellestablish
antibodi
pair
use
sandwich
immunoassay
howev
antigen
compat
antibodi
pair
good
antigen
specif
yet
exist
recent
studi
focus
use
antibodi
array
identifi
cancer
relat
antigen
heterogen
diseas
like
cancer
singl
biomark
expect
captur
complex
diseas
rather
panel
antigen
expect
inform
antibodi
array
provid
suffici
densiti
throughput
parallel
test
mani
biolog
sampl
discov
antigen
across
patient
popul
serum
patient
cancer
prostat
lung
pancrea
bladder
profil
antibodi
array
tabl
sever
antigen
found
differenti
express
cancer
patient
miller
et
al
profil
fluoresc
label
prostat
cancer
sera
identifi
five
protein
differ
cancer
patient
sera
studi
author
improv
detect
limit
antigen
fold
ngml
use
three
dimension
acrylamid
gel
surfac
oppos
tradit
chemic
derivat
planar
surfac
improv
sensit
may
reflect
higher
bind
capac
surfac
improv
abil
preserv
antibodi
function
use
chemistri
observ
detect
antigen
mostli
abund
protein
serum
concentr
either
microgram
milligram
per
millilit
sera
antigen
like
psa
typic
found
rang
nanogram
per
millilit
sera
highli
abund
psa
detect
improv
sensit
assay
sever
studi
use
roll
circl
amplif
rca
enhanc
detect
antigen
serum
patient
pancreat
cancer
lung
cancer
conjug
either
biotin
digoxigenin
antibodi
label
modifi
circular
detect
dna
templat
signal
amplif
rca
improv
limit
detect
antigen
low
ngml
use
method
sever
common
antigen
c
reactiv
protein
serum
amyloid
found
significantli
differ
cancer
sera
compar
respect
control
ensur
respons
due
cross
react
signal
author
confirm
observ
western
blot
analysi
serum
one
challeng
print
antibodi
decid
analyt
target
approach
use
sanchezcarbayoi
et
al
target
gene
overexpress
cancer
gene
overexpress
patient
bladder
cancer
identifi
use
dna
array
antibodi
gene
use
measur
correspond
protein
level
serum
detect
antigen
bias
cell
cycl
regul
protein
cyclin
etc
consid
specif
bladder
cancer
potenti
antibodi
microarray
molecular
profil
biomark
success
demonstr
sever
abovement
studi
howev
sensit
assay
absenc
high
qualiti
antibodi
analyt
specif
reagent
protein
remain
challeng
success
technolog
assay
reli
singl
antibodi
measur
often
reliabl
due
signal
cross
reactiv
requir
follow
experi
elimin
fals
posit
confirm
find
sandwich
assay
avoid
problem
increas
specif
two
antibodi
avail
two
high
qualiti
antibodi
everi
antigen
limit
altern
method
rapidli
produc
divers
content
high
affin
captur
reagent
stabli
print
array
need
address
concern
stabil
specif
divers
current
antibodi
collect
approach
develop
et
al
reli
produc
singl
chain
variabl
fragment
scfv
antibodi
still
contain
antigen
recognit
motif
result
product
fifth
size
whole
antibodi
retain
specif
stabli
produc
e
coli
high
level
use
recombin
scfv
repres
novel
twist
antibodi
array
hold
great
promis
biomark
discoveri
borrebaeck
colleagu
select
human
recombin
scfv
antibodi
fragment
larg
phage
display
librari
develop
recombin
scfv
captur
array
improv
limit
detect
profil
lowabund
protein
analyt
nonfraction
sampl
author
select
surfac
chemistri
improv
bind
capac
scfv
also
label
analyt
biotin
allow
amplif
signal
use
fluoresc
label
streptavidin
approach
yield
picomolar
sensit
multiplex
analysi
low
abund
analyt
complex
sampl
fig
studi
ellmark
et
al
util
approach
gener
scfv
singl
framework
recombin
antibodi
fragment
obtain
phage
display
librari
array
scfv
antibodi
construct
identifi
protein
express
signatur
patient
gastric
adenocarcinoma
set
helicobact
pylori
infect
studi
show
alter
level
interleukin
etc
tissu
infect
h
pylori
onset
tumor
result
alter
abund
interleukin
etc
well
complement
protein
monocyt
chemotact
protein
mcp
howev
find
experiment
valid
anoth
studi
use
recombin
scfv
antibodi
microarray
direct
serum
protein
classifi
metastat
breast
cancer
patient
healthi
control
base
differenti
serum
protein
profil
use
limit
number
serum
sampl
healthi
control
breast
cancer
patient
author
identifi
differ
level
abund
test
protein
chang
mostli
observ
among
sever
interleukin
complement
protein
two
antigen
observ
chang
abund
control
diseas
observ
two
differ
scfv
target
antigen
ad
assur
respons
reflect
chang
specif
target
antigen
difficult
explain
case
multipl
scfv
avail
antigen
one
show
signific
chang
signal
observ
requir
follow
experi
elimin
concern
cross
react
signal
howev
earli
studi
identifi
sever
candid
tumor
associ
inflammatori
marker
like
well
complement
protein
like
alter
level
serum
breast
cancer
patient
tissu
patient
gastric
adenocarcinoma
tissu
h
pylori
infect
tissu
find
requir
valid
demonstr
potenti
recombin
antibodi
microarray
biomark
discoveri
altern
approach
protein
microarray
revers
phase
array
rpa
immobil
sampl
interest
manner
reminisc
dot
blot
array
compris
varieti
sampl
eg
cultur
cell
tissu
lysat
blood
sampl
probe
specif
antibodi
determin
rel
abund
target
antigen
variou
sampl
fig
detect
accomplish
fluoresc
colorimetr
chemiluminesc
amplifi
coupl
detect
antibodi
tyramid
base
avidin
biotin
signal
amplif
system
rpa
first
introduc
paweletz
et
al
author
print
cell
lysat
prostat
cancer
specimen
microdissect
repres
tissu
cell
popul
undergo
diseas
transit
result
studi
demonstr
cancer
progress
associ
increas
phosphoryl
akt
suppress
apoptosi
pathway
well
decreas
phosphoryl
erk
power
applic
revers
phase
array
profil
signal
pathway
variou
cancer
includ
ovarian
prostat
breast
use
antibodi
specif
particular
phosphoprotein
rpa
creat
multiplex
readout
sever
phosphoryl
event
simultan
profil
state
signal
pathway
abund
cellcycl
checkpointrel
protein
dna
repair
capac
assess
peripher
blood
lymphocyt
use
rpa
also
use
find
potenti
therapeut
agent
malign
glioma
translat
research
biomark
discoveri
high
throughput
molecular
profil
human
cancer
cell
line
use
rpa
perform
nishizuka
et
al
profil
human
cancer
cell
line
use
antibodi
product
gene
identifi
candid
previou
dna
microarray
experi
serial
dilut
help
captur
dynam
rang
studi
identifi
two
patholog
marker
villin
moesin
distinguish
colon
ovarian
adenocarcinoma
antibodi
protein
interest
avail
rpa
offer
potenti
rapidli
compar
level
protein
across
mani
sampl
cell
tissu
side
side
array
condit
use
rpa
presuppos
research
alreadi
identifi
analyt
interest
access
high
qualiti
antibodi
avail
use
array
fundament
rpa
singl
antibodi
assay
thu
identifi
antibodi
suffici
specif
requir
care
screen
antibodi
specif
western
blot
well
method
ensur
crossreact
report
signal
moreov
essenti
confirm
find
rpa
use
tradit
assay
monitor
chang
western
blot
thu
rpa
fit
pure
discoveri
tool
valid
tool
humor
immun
respons
detect
cancer
infecti
diseas
autoimmun
diseas
chronic
diseas
standard
approach
detect
humor
immun
respons
reli
elisa
well
well
plate
coat
purifi
antigen
fig
immun
respons
measur
detect
bind
immunoglobulin
bound
antigen
use
appropri
antiimmunoglobulin
standard
elisa
easi
adapt
offer
sensit
method
detect
immun
respons
low
cost
elisa
basic
studi
protein
one
time
cumbersom
costli
use
screen
tool
discov
new
antigen
earli
approach
use
discov
cancer
antigen
elicit
humor
respons
serex
technolog
serolog
analysi
recombin
cdna
express
librari
fig
phagebas
cdna
express
librari
gener
relev
cancer
tissu
use
produc
larg
number
tumor
antigen
e
coli
advantag
approach
express
librari
deriv
gene
express
tumor
thu
produc
antigen
like
relev
diseas
approach
success
discov
antigen
relev
cancer
antigen
discov
date
serex
still
remain
valid
control
studi
determin
respons
diseas
specif
antigen
microarray
emerg
versatil
tool
ht
immun
respons
profil
tabl
array
allow
larg
number
antigen
test
across
mani
serum
sampl
simultan
moreov
replic
array
test
patient
control
sera
discoveri
initi
valid
done
singl
step
earlier
work
antigen
microarray
focus
valid
detect
serum
antibodi
antigen
microarray
reli
print
small
amount
antigen
onto
microscop
featur
planar
surfac
oppos
coat
macroscop
plate
well
fig
rais
concern
integr
antigen
print
storag
whether
adequ
antigen
present
array
sensit
detect
first
test
antigen
micorarray
monitor
immun
respons
demonstr
joo
et
al
well
known
recombin
autoantigen
ro
la
sjorgren
syndrom
cenp
b
crest
syndrom
antinuclear
antigen
rheumatoid
arthriti
sever
other
purifi
either
insect
cell
e
coli
tissu
print
onto
nitrocellulos
membran
array
probe
autoimmun
serum
contain
document
antigen
respons
expect
select
bind
serum
antibodi
respect
antigen
observ
case
test
sensit
detect
author
perform
serial
dilut
serum
establish
detect
limit
serum
antibodi
bind
five
autoantigen
case
sensit
compar
standard
elisa
howev
case
note
sensit
protein
spot
array
advers
affect
upon
storag
similar
studi
perform
robinson
et
al
character
serum
autoimmun
respons
known
autoantigen
eight
autoimmun
diseas
studi
found
serum
antibodi
bind
antigen
select
observ
fold
higher
sensit
convent
elisa
demonstr
use
overlap
peptid
immunodomin
epitop
identifi
immun
respons
subtyp
use
subtyp
specif
detect
antibodi
earli
report
establish
sensit
specif
antigen
array
adequ
detect
serum
antibodi
autoimmun
diseas
mani
diseas
immun
respons
poorli
character
discoveri
new
inform
antigen
would
benefit
whole
proteom
could
analyz
earli
approach
gener
cdna
express
librari
human
tissu
human
fetal
brain
creat
redund
set
cdna
clone
express
e
coli
spot
onto
larg
filter
without
purif
array
probe
either
pool
sera
patient
alopecia
areata
plasma
individu
patient
dilat
cardiomyopathi
dcm
author
identifi
antigen
elicit
immun
respons
two
pool
patient
sera
alopecia
areata
antigen
two
patient
dcm
confirm
respons
antigen
purifi
print
focus
array
test
individu
sera
patient
control
alopecia
areata
studi
antigen
confirm
antigen
continu
show
elev
respons
patient
dcm
share
immun
respons
observ
patient
alopecia
areata
dcm
approach
offer
advantag
serex
technolog
use
cdna
librari
rich
sourc
antigen
combin
conveni
print
express
product
parallel
process
potenti
drawback
use
cdna
librari
challeng
express
rare
transcript
presenc
frame
truncat
gene
product
earlier
studi
estim
cdna
librari
may
yield
clone
produc
polypeptid
natur
read
frame
establish
method
ht
product
antigen
reli
express
purif
recombin
protein
e
coli
although
human
protein
express
well
e
coli
good
success
observ
pathogen
protein
rapid
method
identifi
immunodomin
antigen
infecti
agent
import
develop
effect
vaccin
current
strategi
use
live
attenu
strain
vaccin
lead
toxic
effect
caus
non
immunogen
antigen
challeng
identifi
rare
immunodomin
antigen
confer
protect
within
larg
pathogen
proteom
recent
effort
sequenc
annot
clone
full
length
orf
sever
pathogen
success
mani
reagent
publicli
avail
remain
develop
method
produc
protein
print
high
densiti
protein
array
earli
work
focus
develop
subproteom
array
proteom
smaller
pathogen
identifi
immunodomin
antigen
studi
steller
et
al
produc
phase
variabl
gene
nisseria
meningitidi
test
immun
respons
sera
patient
infect
bacteri
mening
found
test
antigen
immunogen
least
one
patient
respons
nine
antigen
test
share
least
three
patient
respons
outer
membran
protein
call
opav
detect
patient
test
anoth
studi
zhu
et
al
focus
identifi
immun
respons
patient
canada
china
suffer
sever
acut
respiratori
syndrom
sar
due
infect
coronaviru
construct
array
repres
protein
six
coronavirus
test
sera
infect
patient
healthi
control
small
doubl
blind
studi
use
serum
sampl
patient
control
found
coronaviru
protein
microarray
abl
classifi
patient
sensit
specif
observ
antigen
microarray
sensit
case
sensit
commerci
avail
elisa
detect
immun
respons
viral
antigen
anoth
studi
use
commerci
avail
coupl
vitro
transcript
translat
ivtt
e
coli
extract
produc
pathogen
protein
test
serum
antibodi
use
genom
dna
orf
amplifi
pcr
recombin
express
vector
express
use
e
coli
ivtt
express
product
directli
print
without
purif
onto
nitrocellulos
membran
approach
success
use
detect
protein
signal
base
epitop
tag
vaccinia
viral
protein
protein
francisella
tularensi
vaccinia
antigen
test
serum
vaccin
human
infect
mice
commonli
recogn
antigen
respons
bias
toward
membran
protein
serv
favor
candid
diagnost
vaccin
develop
f
tularensi
antigen
array
probe
serum
immun
mice
reveal
alreadi
document
antigen
previous
unreport
candid
antigen
major
immunodomin
respons
bias
toward
membran
protein
use
ivtt
extract
produc
protein
amplifi
orf
offer
advantag
convent
vivo
method
simpl
fast
easi
adapt
ht
applic
surprisingli
studi
show
membran
protein
produc
ivtt
serv
viabl
antigen
serum
antibodi
bind
approach
work
well
detect
strong
respons
pathogen
protein
howev
approach
costli
protein
yield
low
moreov
print
unpurifi
protein
may
affect
much
antigen
present
featur
major
print
protein
lysat
compet
express
antigen
bind
array
surfac
higher
background
signal
may
also
observ
cross
react
serum
antibodi
spot
lysat
protein
serum
antibodi
respons
autoantigen
tumor
antigen
vari
significantli
titer
respons
moreov
target
antigen
could
product
human
gene
includ
variou
splice
form
modifi
posttransl
glycosyl
myristoyl
acetyl
etc
therefor
discov
new
serum
antibodi
human
protein
requir
method
produc
larg
number
protein
ht
method
sensit
detect
rare
serum
antibodi
one
approach
use
revers
phase
array
technolog
entail
immobil
complex
protein
lysat
biolog
sampl
interest
manner
reminisc
dot
blot
fig
array
probe
serum
antibodi
discov
immun
respons
studi
bouwman
et
al
took
lysat
diseaserel
cell
line
separ
lysat
fraction
liquid
chromatographi
fraction
lyophil
resuspend
print
buffer
print
onto
glass
microscop
slide
done
prostat
lung
cancer
cell
line
deriv
diseas
specif
panel
antigen
fraction
discov
serum
antibodi
found
fraction
produc
higher
signal
prostat
cancer
patient
control
fraction
ovarian
cancer
sera
respond
antigen
within
fraction
identifi
studi
later
studi
madozgurpid
author
highlight
challeng
identifi
antigen
fraction
first
put
antigen
could
spread
mani
fraction
due
separ
process
second
antigen
could
mani
protein
given
fraction
address
group
immunoreact
fraction
order
elut
pattern
immunoreact
use
multipl
ms
base
approach
followup
experi
identifi
immunoreact
antigen
found
fraction
one
protein
particular
human
kallikrein
known
overexpress
prostat
cancer
identifi
put
tumor
antigen
sensit
specif
serum
respons
determin
test
serum
sampl
purifi
protein
spot
array
revers
phase
array
approach
sever
advantag
discov
serum
antibodi
first
provid
rapid
sourc
antigen
without
need
gener
cdna
express
librari
reli
avail
clone
orf
second
extend
tissu
patient
may
contain
relev
protein
test
protein
nativ
diseasespecif
ptm
aberr
gene
product
unbias
approach
requir
inform
priori
antigen
test
relat
method
develop
qin
et
al
call
revers
captur
array
also
reli
cellular
antigen
test
serum
antibodi
fig
isol
nativ
antigen
cell
author
use
commerci
antibodi
array
contain
antibodi
cell
lysat
prostat
cancer
cell
line
incub
antibodi
array
allow
appropri
antigen
bind
cognat
target
antibodi
test
antibodi
occup
separ
experi
fluoresc
label
lysat
ad
array
reveal
antibodi
bound
label
protein
determin
captur
antigen
recogn
serum
antibodi
serum
igg
purifi
pool
sera
directli
label
prior
incub
antigen
bound
array
two
antigen
name
found
elev
serum
respons
later
confirm
western
blot
analysi
follow
studi
use
individu
serum
sampl
oppos
pool
sera
fail
identifi
domin
respons
test
studi
respons
observ
small
subset
patient
consid
signific
rais
concern
pool
sera
strong
respons
singl
serum
may
domin
outcom
mani
interest
antigen
occur
low
abund
biolog
specimen
one
techniqu
attempt
enrich
interest
antigen
use
recombin
phage
display
technolog
cdna
express
librari
deriv
relev
tissu
construct
phage
express
e
coli
phage
product
elicit
immun
respons
captur
serum
igg
bound
bead
bound
phage
elut
amplifi
reselect
continu
enrich
respond
phage
fig
approach
appli
detect
serum
antibodi
ovarian
prostat
cancer
patient
sera
detect
ovarian
cancer
antigen
panel
show
sensit
specif
respect
antigen
panel
reveal
sensit
specif
respect
detect
prostat
cancer
phage
technolog
combin
protein
microarray
provid
power
techniqu
allow
rare
diseasespecif
antigen
enrich
test
across
mani
sampl
worth
note
amplif
process
finit
therefor
increas
round
biopan
enrich
phage
antigen
may
select
fast
grow
antigen
oppos
tight
binder
reduc
divers
put
antigen
pool
due
select
anoth
approach
express
protein
orf
librari
well
annot
orf
librari
ensur
gene
clonal
isol
fulli
sequenc
verifi
minim
redund
provid
templat
full
length
gene
unlik
convent
cdna
librari
recent
work
hudson
et
al
use
commerci
avail
human
protein
array
protein
print
duplic
test
sera
patient
ovarian
cancer
protein
express
use
insect
cell
purifi
via
glutathion
transferas
gst
fusion
protein
print
onto
nitrocellulos
membran
found
somewhat
surprisingli
larg
number
protein
specif
respons
sera
patient
healthi
control
howev
respons
suffici
differenti
cancer
healthi
individu
author
sought
measur
amount
select
immunogen
antigen
ovarian
tissu
found
lamin
ac
show
high
level
stain
compar
non
cancer
tissu
isol
individu
advantag
use
partial
purifi
protein
protein
readili
address
format
obscur
overabund
highli
express
protein
recent
past
signific
improv
avail
resourc
develop
novel
proteom
technolog
enabl
discoveri
protein
biomark
antibodi
microarray
use
profil
biolog
sampl
like
serum
diseas
specif
peptid
antigen
howev
approach
reli
singl
antibodi
measur
often
specif
enough
possibl
cross
react
protein
speci
approach
requir
orthogon
test
confirm
specif
signal
risk
cross
react
signal
consider
reduc
sandwich
assay
howev
wellestablish
antibodi
pair
antigen
exist
tremend
need
highli
specif
antibodi
altern
high
affin
captur
reagent
function
context
protein
microarray
antigen
microarray
emerg
power
platform
discov
serum
antibodi
potenti
biomark
larg
collect
orf
librari
increas
number
techniqu
readili
avail
product
detect
protein
effort
sever
group
earli
detect
research
network
edrn
nation
institut
allergi
infecti
diseas
niaid
juvenil
diabet
research
foundat
jdrf
other
made
signific
stride
toward
systemat
collect
biolog
sampl
varieti
diseas
test
culmin
advanc
enabl
identif
sever
candid
serum
antigen
antibodi
marker
sever
diseas
includ
infecti
diseas
autoimmun
diseas
cancer
remain
clinic
valid
marker
measur
util
biomark
glycogensynthas
kinas
antibodi
array
assay
format
two
assay
format
commonli
use
direct
labelingsampl
directli
chemic
modifi
fluoresc
label
b
sandwich
immunoassay
detect
captur
analyt
accomplish
fluoresc
label
second
antibodi
bind
differ
epitop
captur
antibodi
direct
label
approach
depend
entir
specif
captur
antibodi
therefor
prone
aberr
signal
sampl
eg
lysat
bodi
fluid
incub
nativ
antigen
captur
antibodi
array
immunoglobulin
purifi
patient
sera
label
differ
cyanin
dye
ad
captur
antigen
array
case
slide
scan
data
analyz
antigen
confirm
investig
valid
hit
experiment
method
eg
western
blot
elisa
immunohistochemistri
indic
ye
indic
valid
unless
otherwis
note
biomark
list
valid
independ
sampl
set
patient
control
